CRVO — CervoMed Inc.

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About CervoMed Inc.

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$3.44
Market Cap$34.8M
Float6.3M
Shares Outstanding9.3M
Price/Sales (TTM)8.69
vs. Analyst Target+543.7% to analyst PT
Operating Margin (TTM)-95479.24%
Revenue (TTM)$4.0M
Dividend RateNone
Analyst Target Price$22.14 (7 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$14.2M -$103,168 -$15.8M
2021 N/A -$24.1M -$93,416 -$15.9M
2022 N/A -$15.6M -$1.3M -$3.5M
2023 $7.1M -$2.2M -$1.3M -$7.8M
2024 $9.7M -$16.3M -$9.1M -$18.2M
2025 $4.0M -$27.0M N/A -$28.3M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Mar 2025 $1.9M -$4.9M
Jun 2025 $1.8M -$6.3M
Sep 2025 $322,569 -$7.7M
Dec 2025 $8,726 -$8.1M

Ownership & Float

Insider Ownership32.8%
Institutional Ownership14.7%
Short Float4.5%
% of All Funds Holding0.41%
Number of Funds Holding34

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$3.89Near-term / short-term trend
Weekly40-Week SMA$6.61Medium-term trend
Weekly80-Week SMA$6.70Cyclical trend (business cycle)
Weekly200-Week SMA$9.25Secular trend (multi-year)
Monthly10-Month SMA$6.28Near-term monthly trend
Monthly20-Month SMA$6.70Medium-term monthly trend
Monthly40-Month SMA$8.97Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$2.30 support 8.81x 13 months ago
$12.70 resistance 6.18x 16 months ago

Historical Earnings Reactions (44 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.09% 0.00% 43.18% 9.38% -15.38%
1 Day 0.14% -0.92% 27.27% 14.86% -11.29%
1 Week 0.38% -1.25% 34.09% 51.51% -64.52%
2 Weeks 0.78% -4.33% 38.64% 82.14% -41.94%
1 Month -5.33% -8.40% 38.64% 130.43% -84.61%

Next earnings: May 11, 2026

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan-2.8%33.3%18
Feb5.9%44.4%18
Mar22.2%50.0%18
Apr-0.2%33.3%18
May9.4%41.2%17
Jun-13.5%16.7%18
Jul-2.0%38.9%18
Aug-4.1%33.3%18
Sep-6.0%38.9%18
Oct-9.5%22.2%18
Nov-9.2%33.3%18
Dec-7.0%44.4%18

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.01% 33.8% 848
Tuesday -0.33% 30.3% 930
Wednesday 0.26% 35.5% 927
Thursday 0.08% 31.3% 908
Friday 1.07% 35.1% 905

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 14.7%

Insider Transactions — Smart Summary

Total insider ownership: 32.8%

Founder-led management: John Alam (Chief Executive Officer)

12-Month Insider Activity Summary

Total Filings10
Net Value+$455,071.33
Net Shares Change92,000
% of Float1.5%
C-Suite Filings7
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
ALAM JOHN J CEO and President +$282,651.48 3 5 buy
Gregoire Sylvie +$282,651.396 3 5 buy
Winton Matthew Chief Commercial and Business +$117,130 2 2 buy
ELDER WILLIAM ROBERT CFO, GC and Secretary +$55,289.85 2 2 buy

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-11-13 – 2025-11-19 10 4 +$737,722.726 7 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2025-11-19 ALAM JOHN J CEO and President +$182,736 Transaction at $8.46, now -59.3%
2025-11-19 Gregoire Sylvie +$182,736 Transaction at $8.46, now -59.3%
2025-11-17 ALAM JOHN J CEO and President +$59,100.93 Transaction at $7.55, now -54.4%
2025-11-19 Winton Matthew Chief Commercial and Business +$41,430 Transaction at $8.29, now -58.5%
2025-11-19 ELDER WILLIAM ROBERT CFO, GC and Secretary +$29,249.85 Transaction at $8.36, now -58.8%
2025-11-17 Gregoire Sylvie +$59,100.846 Transaction at $7.54, now -54.4%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for CervoMed Inc. (CRVO) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for CRVO on Trend Edge →